Grace Colon, Ph.D.President & CEO at InCarda Therapeutics
Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she serves on the board of directors of ProterixBio (Executive Chairman; formerly CEO), CareDx (NASDAQ:CDNA) and Cocoon Biotech, and formerly on the boards of Paradigm Diagnostics and PerceptiMed. She was also formerly a Partner and Senior Advisor at New Science Ventures, a NY-based venture capital firm with over $700M under management, and held executive and managerial roles at Intrexon Corporation, Gilead Sciences, Affymetrix, the International Genomics Consortium and McKinsey & Co. Dr. Colón received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering.